Enzyme conjugate and prodrug cancer therapy
US9987241B2 · kind B2 · utility
1Cited by
51References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 25, 2015 |
| Grant date | Jun 5, 2018 |
| Priority date | — |
| Expiry date | Jan 26, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y404/01001
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method and composition for treating a cancerous tumor in a subject by targeting the tumor's vasculature using an enzyme conjugate comprising a ligand which binds to endothelial cells in the tumor vasculature and converts a prodrug administered to the subject into an anticancer drug in the tumor vasculature.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.